Denali Therapeutics (DNLI) Q2 2026 Earnings Report

The earnings call communicated a strong, constructive start to commercialization with meaningful early revenue ($3.6M), rapid payer progress (>50% commercial lives) and platform validation via AVLAYAH, supported by a robust pro forma cash position (> $1.1B) and multiple clinical programs advancing toward 2027 readouts. Near-term challenges include variability in revenue and patient initiation timing due to weight-based dosing and infusion logistics, limited disclosed patient-level metrics, some program timing shifts (DNL593), and competitive/coverage risks. On balance, the positive commercial and platform milestones materially outweigh the near-term operational and timing uncertainties.

Denali's guidance emphasized early-launch trajectory and near-term milestones: AVLAYAH generated $3.6M of net product revenue in Q2 and management expects Q3 net product revenue of $10–12M, with the company providing next-quarter revenue guidance for the first two quarters of the launch; balance sheet strength includes ~ $940M in cash, cash equivalents and marketable securities at quarter end plus $195M PRV proceeds in July for pro forma cash > $1.1B. Key financials: R&D expense was $97M (vs. $102.7M a year ago) and SG&A was $36.3M (vs. $32.3M). Commercial and access metrics: an estimated ~2,000 worldwide MPS II addressable patients (~500 U.S. prevalent, ~375 U.S. label-eligible), ~30 births/year, >50% of commercial lives already covered, 14 state Medicaid programs publicly listing coverage, and >100 families engaged (>25% of eligible U.S. patients). Clinical and pipeline timing: DNL628 biomarker data expected H1 2027, DNL921 initial safety/POC data in 2027, DNL593 databook moved to H1 2027, the COMPASS confirmatory study completes at the end of next year, and corporate 2026–2028 goals include building two commercial brands, generating five clinical PoCs, and advancing 4–6 additional programs into the clinic.